MN-DIGI-INTERNATIONAL
Digi International, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched Digi Containers, a software service that enables the development and operation of custom applications on Digi cellular routers that run DAL OS. Digi Containers leverage the Digi Remote Manager® platform as the central portal for deploying and managing these applications.
The Digi Containers service helps developers take the fullest advantage of edge computing by providing the flexibility to deploy new services and apps while consolidating edge-processing hubs. These edge applications offer low latency and near-real-time responsiveness with the agility to respond to evolving use cases.
Through Digi Containers, developers employ Lightweight Linux Containers (LXCs) — essentially virtual machines (VMs) that share the physical device’s running kernel. This enables processes inside a container to run at native speed as if they are actually running directly on the host device. Since containers are lightweight and portable, they offer both security and flexibility. This enables developers to expand on the capabilities of Digi solutions to support specific needs.
As a value-added service for Digi cellular routers, Digi Containers enable users to upload, manage, deploy, and monitor container-based applications through Digi Remote Manager. This empowers companies to orchestrate and manage a complex series of containers in various structures and configurations. Digi Containers provide:
- Portability – A containerized application can be deployed in private and public clouds. Companies gain flexibility because they can easily move workloads among environments and providers.
- Scalability – Containers can scale horizontally (i.e., you can “clone” identical containers within the same cluster to expand capacity/throughput as needed). By running only what is needed, when needed, costs decrease significantly.
- Increased security – By design, containers are inherently isolated. If one container is compromised, others won’t be affected.
- Speed – Autonomy from the operating system gives greater control. You can start/stop a container in seconds. You achieve faster development and operational speed and a faster and smoother user experience.
- Efficiency – Since a separate operating system isn’t required, containers require fewer resources than VMs. You can run several containers on a single server. Less hardware means lower costs and fewer points of failure.
“The launch of Digi Containers unlocks the power of edge computing on Digi cellular routers,” said Kinana Hussain, Vice President of Product Management. “By building in the embedded software environment on our devices, along with their inherent computational capabilities, developers can tap into a rich and growing set of features, capabilities, and services. These are all signed, vetted, and distributed as part of the Digi TrustFence® security framework to more easily create and support a variety of demanding containerized applications in the enterprise, industrial, and transportation markets.”
Digi Enhances Network Analytics Application
Recently, Digi also upgraded Digi intelliFlow® in Digi Remote Manager, further strengthening Digi’s edge-to-cloud software stack. Digi intelliFlow provides a graphical visualization of network application data, focusing on the top 10 users or top 10 destinations. This intuitive representation of network activity allows organizations to update settings on Digi routers or tailor the network to the site’s needs. Digi intelliFlow provides recent data and a historical reference to keep networks running smoothly. intelliFlow addresses excessive data usage with custom alarms that alert administrators when data limits are approaching.
“Our long-term vision is to enable a full suite of market vertical-specific value-added services that leverage our robust edge-to-cloud software stack to help our customers maximize their IoT investments while focusing on their core business,” said Hussain.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
